TG Therapeutics (TGTX) Misses Q1 EPS by 6c

TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c